- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01902394
The Addition of Whole Grains to the Diets of Adults: A Study of Digestive Health and Natural Defenses
The purpose of this study is to determine if substituting whole grains for refined grains in the diets of healthy adults over a period of 6 weeks alters the composition of the bacteria in the gut, and has beneficial effects on immune function, digestive health, cardiovascular health, regulation of body weight and composition, and vitamin K status.
The investigators hypothesize that whole grain consumption over a period of 6 weeks will alter the gut microflora toward a more beneficial bacterial profile, improve the immune response while reducing oxidative stress and inflammatory markers, have favorable effects on factors influencing the regulation of body weight and composition,increase bacterial vitamin K synthesis, and beneficially effect surrogate markers of cholesterol synthesis/absorption, vitamin D concentrations, and whole genome DNA methylation patterns. In statin users it is hypothesized that, consumption of whole grains will alter statin pharmacokinetics by decreasing rate of statin absorption, resulting in more sustained plasma concentrations.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- HNCRA at Tufts University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Subjects Inclusion Criteria
- Healthy male and female subjects aged 40-65 y (women must be > 1 year postmenopausal or had both ovaries removed, if premenopausal).
- Body mass index (BMI) 20-35 kg/m.2
Pass screening blood and urine tests
- Creatinine ≤ 1.5 mg/dL
- glutamic oxaloacetic transaminase/serum glutamate pyruvate transaminase/total bilirubin ≤ twice the upper limit of normal range
- Fasting glucose <125 mg/dL
- hematocrit ≥ 32%
- white blood cell count ≥ 1.8 x 103/mm3 (M)
- PLT ≥ 100 x 103/mm3 (thou/µL)
- Must be willing to be randomized.
- Those randomized to either the WG or RG groups must be willing to consume only study foods and beverages provided.
Exclusion Criteria
- Self reported weight change >4kg within the past 3 months.
- Have participated in a weight loss program within the last 3-months; eligible if in weight reduction program to maintain body weight.
- Not willing to reduce habitual daily fiber intake (including prebiotics) within 2 wk prior to enrollment to < ~7g/1000kcal/d for men, or <~8g/1000kcal/d for women if currently consuming greater amounts.
- Not willing to stop consumption of probiotic or prebiotic supplements within 2 weeks prior to start of study if currently taking these, as well as during study participation.
- Vegetarian diet.
- Not willing to stop taking multivitamins, and supplements (with the exception of vitamin D and calcium), including fish oil or n-3 fatty acids and herbal supplements, for 30 days prior to or during study participation, if currently taking these.
- Regular use of laxatives, stool softeners, or anti-diarrheal medications, and medications influencing food intake and/or appetite.
- Not willing to undergo a 3-month washout period after colonoscopy prior to enrollment, and not willing to defer colonoscopy until after study completion.
- Eating disorder within the past 10 years.
- Disinhibited eating behavior as indicated by a score above 12 on the Three Factor Eating Questionnaire.
- Food allergies or aversions or other issues with foods that would preclude use of study diets, including gluten, milk, nuts, or eggs.
- Individuals identified during screening as having barriers expected to deter compliance with dietary requirements (e.g., stated dislike of study foods, inadequate resources to store and reheat meals, inability to adhere to food pick-up schedule).
- Alcohol consumption >2 drinks per day.
- Not willing to abstain from alcohol consumption during the study.
- Smoking or using nicotine containing products in the last 6 months.
- Use of aspirin, non-steroidal anti-inflammatory medications (NSAIDs) or antihistamine prescribed by a physician or clinician, or the inability to discontinue the use of these substances for 72 hrs before first day blood draw until 48 hrs after DTH implant (i.e. after second reading).
- Use of anabolic steroids, insulin, growth hormone or testosterone.
- Type I or type II diabetes.
- Uncontrolled major illnesses. (Will include if stable on drugs used to control cardiovascular, liver, and renal diseases, asthma, and dysphagia).
- Current use of proton pump inhibitors and H2 blockers to control acid-reflux/heart burn
- Use of medications which interfere with energy metabolism including oral glycemic agents and insulin.
- Uncontrolled hypertension as determined by study physician or nurse.
- Use of immunosuppressive drugs.
- Active cancer or current cancer diagnosis (except non-melanoma skin cancer).
- Active infection within 2 weeks of study enrollment, blood draws or skin tests; however, may participate if admission is postponed or study activity is rescheduled > 2 weeks after resolution of symptoms.
- Any antibiotic use within the past 3 months, except topical antibiotic use.
- History of dysphagia, malabsorptive disorders, inflammatory bowel disease or other gastrointestinal disorders such as ulcerative colitis, Crohn's disease, celiac disease , chronic diarrhea or constipation.
- Gastric bypass or other surgery for weight loss.
- Splenectomy or partial splenectomy.
- Autoimmune diseases such as rheumatoid arthritis and psoriasis. Autoimmune thyroid disease that has been treated and with stable replacement doses is not an exclusion.
- Taking warfarin or coumadin any time during the previous 6 months.
- Current diagnosis of or treatment for psychosis (i.e. schizophrenia, etc.). Include depression if has been stable on treatment regimen for > 6 months.
- Blindness or deafness not corrected with use of glasses and hearing aids.
- Does not speak English; due to insufficient funds to hire a translator and to get all study materials translated into another language to allow us to recruit non-English speaking participants non-English speakers will not be eligible to participate.
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Whole grain rich diet
Participants in the whole grain (WG) group will receive a diet providing 100% of energy requirements in a diet rich in whole grains.
|
Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
|
PLACEBO_COMPARATOR: Refined grain rich diet
Participants in the refined grain (RG) group will receive a diet providing 100% of energy requirements in a diet rich in refined grains.
|
Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
|
NO_INTERVENTION: Negative control
Subjects randomized to the negative control group will consume their own usual diet (i.e.
not receive foods and beverages from the study).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in T Cell-mediated immunity
Time Frame: week 2 of washout diet and week 6 of diet intervention
|
Delayed-type hypersensitivity (DTH) and lymphocyte proliferation will be measured at baseline (week 2 of washout period) and at week-6 of the diet intervention to assess adaptive immune function, specifically T cell-mediated immunity.
|
week 2 of washout diet and week 6 of diet intervention
|
change in Lymphocyte proliferation
Time Frame: week 2 of washout diet and week 6 of diet intervention
|
Whole blood collected at baseline (week 2 of washout period) and at week-6 of the diet intervention will be investigated for the ability of lymphocytes to proliferate by quantifying the incorporation of tritium following mitogen stimulation.
|
week 2 of washout diet and week 6 of diet intervention
|
change in Natural Killer Function
Time Frame: week 2 of washout diet and week 6 of diet intervention
|
The ability of peripheral blood mononuclear cells to bind and kill leukemia cells will be measured at baseline (week 2 of washout period) and at week-6 of the diet intervention
|
week 2 of washout diet and week 6 of diet intervention
|
change in Cytokines
Time Frame: week 2 of washout diet and week 6 of diet intervention
|
Peripheral blood and stool samples will be analyzed at baseline (week 2 of washout diet) and week-6 of diet intervention for cytokines.
|
week 2 of washout diet and week 6 of diet intervention
|
change in Salivary immunoglobulin A (IgA)
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Salivary IgA will be analyzed at baseline (week 2 of washout period) and at week-6 of the diet intervention.
|
week 2 of washout diet and week 6 of intervention diet
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in gut microbiota composition
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Phylogenetic composition and relative abundance of bacteria in stool will be analyzed from 24-hour fresh sample collected at baseline (week 2 of washout diet) and at week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in cardiovascular health risk factors
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Consumption of the whole grain (WG) diet will be beneficial for multiple outcomes of cardiovascular health including a favorable blood lipid profile (low density lipoprotein, very low-density lipoprotein, high density lipoprotein, total cholesterol and triglycerides), and a decrease in blood pressure, and in oxidative stress status (secondary hypothesis).
|
week 2 of washout diet and week 6 of intervention diet
|
change in vitamin K status
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Fecal menaquinones concentrations; Fasting serum phylloquinone and menaquinones concentration from 72-hour stool collected at baseline (week 2 of washout diet) and at week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in body composition
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Fat and fat free mass; waist and hip circumference
|
week 2 of washout diet and week 6 of intervention diet
|
change in appetite
Time Frame: Weekly for 8 weeks
|
Visual analog scales to assess hunger, fullness and satisfaction while on the study diet
|
Weekly for 8 weeks
|
change in fasting gut hormone concentration
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Plasma glucagon-like peptide-1 and peptide-YY will be measured from blood samples collected at baseline (week 2 of washout diet) and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in fasting serum leptin
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
|
change in glycemic regulation
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
48 hr continuous glucose monitoring; fasting serum glucose; fasting serum insulin; HOMA-IR
|
week 2 of washout diet and week 6 of intervention diet
|
change in resting energy metabolism
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Resting energy expenditure; substrate oxidation at rest
|
week 2 of washout diet and week 6 of intervention diet
|
change in eating behaviors
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Questionnaires will be administered at baseline (week 2 of washout diet) and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in quality of life
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Questionnaires will be administered at baseline (week 2 of washout diet) and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in breath hydrogen and methane
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
|
change in stool pH
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in 72hr fecal weight
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in stool water content
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in total stool anaerobic and aerobic bacterial counts
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in stool energy content
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in DNA methylation
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
|
change in concentrations of the cholesterol synthesis (squalene, desmosterol, lathosterol) and absorption (campesterol, sitosterol, cholestanol) markers
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
Plasma squalene, desmosterol, lathosterol), campesterol, sitosterol, and cholestanol concentrations will be measured at baseline (week 2 of washout diet) and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
change in serum vitamin D
Time Frame: week 2 of washout diet and week 6 of intervention diet
|
week 2 of washout diet and week 6 of intervention diet
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Karl JP, Meydani M, Barnett JB, Vanegas SM, Barger K, Fu X, Goldin B, Kane A, Rasmussen H, Vangay P, Knights D, Jonnalagadda SS, Saltzman E, Roberts SB, Meydani SN, Booth SL. Fecal concentrations of bacterially derived vitamin K forms are associated with gut microbiota composition but not plasma or fecal cytokine concentrations in healthy adults. Am J Clin Nutr. 2017 Oct;106(4):1052-1061. doi: 10.3945/ajcn.117.155424. Epub 2017 Aug 16.
- Vanegas SM, Meydani M, Barnett JB, Goldin B, Kane A, Rasmussen H, Brown C, Vangay P, Knights D, Jonnalagadda S, Koecher K, Karl JP, Thomas M, Dolnikowski G, Li L, Saltzman E, Wu D, Meydani SN. Substituting whole grains for refined grains in a 6-wk randomized trial has a modest effect on gut microbiota and immune and inflammatory markers of healthy adults. Am J Clin Nutr. 2017 Mar;105(3):635-650. doi: 10.3945/ajcn.116.146928. Epub 2017 Feb 8.
- Karl JP, Meydani M, Barnett JB, Vanegas SM, Goldin B, Kane A, Rasmussen H, Saltzman E, Vangay P, Knights D, Chen CO, Das SK, Jonnalagadda SS, Meydani SN, Roberts SB. Substituting whole grains for refined grains in a 6-wk randomized trial favorably affects energy-balance metrics in healthy men and postmenopausal women. Am J Clin Nutr. 2017 Mar;105(3):589-599. doi: 10.3945/ajcn.116.139683. Epub 2017 Feb 8. Erratum In: Am J Clin Nutr. 2017 Aug;106(2):708.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2720
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Digestive Health and Immune Function
-
University of California, DavisCalifornia Walnut CommissionCompletedImmune Function | Cardiovascular HealthUnited States
-
USDA, Western Human Nutrition Research CenterCompletedGut Microbiome | Gut Health | Yogurt Intake | Gastrointestinal Immune FunctionUnited States
-
University of CopenhagenUniversity of Aarhus; Arla Foods; Arla Foods IngredientsCompletedAppetite Regulation | Muscle Function | Cardiometabolic Health | Bone HealthDenmark
-
University of CopenhagenAalborg University Hospital; University of WaterlooCompletedCognitive Function | Cardiometabolic HealthDenmark
-
Applied Science & Performance InstituteTrue Eye Experts - New TampaCompletedCognitive Function | Vision | Eye HealthUnited States
-
BIO-CAT Microbials, LLCOhio State University; Biofortis Clinical Research, Inc.CompletedImmune Health | Gastrointestinal Health | Digestive HealthUnited States
-
BIO-CAT Microbials, LLCBiofortis Clinical Research, Inc.CompletedImmune Health | Cardiovascular Health | Gastrointestinal Health | Digestive HealthUnited States
-
Vita Naturel, LLCUniversity of South Alabama; University of North Carolina at Asheville; Braini...Completed
-
Open UniversityNetherlands Organisation for Scientific Research; Aker Biomarine Antarctic AS; Omegametrix GmbH and other collaboratorsCompletedCognitive Function | Mental Health | Academic PerformanceNetherlands
-
Concordia University WisconsinNot yet recruitingObesity | Weight Management | Exercise Tolerance | Cardiovascular Health | Digestive Health | General Health and Wellness | Energy and Vitality | Cognitive Function and Mental Health | Bone and Joint Health | Skin, Hair, and Nail Health | Immune Support | Sports Performance and Recovery | Sleep and Relaxation | Anti...
Clinical Trials on Whole grains
-
NYU Langone HealthCompletedHypertension | Obesity | Pregnancy Related | Diet Modification | Birth Weight | Blood Pressure | Pre-Eclampsia | Breast FeedingUnited States
-
USDA, Western Human Nutrition Research CenterCompletedFood PreferencesUnited States
-
The Cleveland ClinicNestléCompletedObesity | Overweight | Pre-diabeticUnited States
-
Federico II UniversityCompleted
-
Lund UniversityRegion SkaneCompletedCardiovascular Diseases | Hypertension | Overweight | Diabetes Type 2 | Abdominal ObesitySweden
-
Yonsei UniversityCompleted
-
Yonsei UniversityCompletedImpaired Fasting Glucose | Newly Diagnosed Type 2 DiabetesKorea, Republic of
-
University of California, San DiegoSuspendedA Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With ObesityObesity | Insulin ResistanceUnited States
-
Sultan Qaboos UniversityNot yet recruitingDepressive Disorder, Major
-
Plexus WorldwideGeorge Mason UniversityUnknown